---
title: "Decoy Therapeutics (DCOY) news: reverse split and delisting"
url: "https://aibio.space/companies/decoy-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "DCOY reverse split, delisting, offering and merger news: Salarius Pharmaceuticals (now Decoy Therapeutics) gets Nasdaq delisting notice, plans appeal."
---

DCOY Decoy Therapeutics Inc. NASDAQ · United States

# Decoy Therapeutics (DCOY) news DCOY reverse split, delisting, offering and merger news

Listings · 2026-01-02

## [Salarius Pharmaceuticals (now Decoy Therapeutics) gets Nasdaq delisting notice, will appeal](https://aibio.space/news/salarius-pharmaceuticals-now-decoy-therapeutics-gets-nasdaq-delisting-2/)

Nasdaq said on December 31, 2025 that the company missed the $1.00 minimum bid price and gets no grace period. Suspension is set for January 9, 2026 unless it appeals by January 7, 2026.

## Latest Decoy Therapeutics news

1. 2025-10-06 Listings [Salarius (now Decoy Therapeutics) says share sales lift equity above Nasdaq minimum](https://aibio.space/news/salarius-now-decoy-therapeutics-says-share-sales-lift-equity-above/) Salarius said $2.4 million from an at-the-market program and $3.8 million from C/M Capital Master Fund, LP lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The figure is preliminary, and Nasdaq has not yet confirmed compliance.
2. 2025-06-11 Mergers [Salarius (now Decoy Therapeutics) cuts its valuation to $2.31 million in merger deal](https://aibio.space/news/salarius-now-decoy-therapeutics-cuts-valuation-2-31-million-merger/) Salarius cut its relative valuation in the Decoy merger from $4.6 million to $2.31 million, so its legacy holders would keep 7.6% of the combined company instead of 14.1%. The 8-K blames "substantial deterioration" in its share price.
3. 2025-04-25 Listings [Salarius Pharmaceuticals (now Decoy Therapeutics) gets Nasdaq delisting notice, plans appeal](https://aibio.space/news/salarius-pharmaceuticals-now-decoy-therapeutics-gets-nasdaq-delisting/) Nasdaq says the stock's bid price was below $1.00 for 30 consecutive business days and, after a recent reverse stock split, no compliance period applies. The company plans to appeal by April 30, 2025.
4. 2024-12-13 Financings [Salarius Pharmaceuticals (now Decoy Therapeutics) signs equity line for up to $10 million](https://aibio.space/news/salarius-pharmaceuticals-now-decoy-therapeutics-signs-equity-line-up/) Salarius Pharmaceuticals agreed on December 12, 2024 to let C/M Capital Master Fund, LP purchase up to $10 million of its common stock over 36 months, once a resale registration is effective. The 8-K names no placement agent or counsel, and it gives the company's Nasdaq symbol as SLRX.

## Decoy Therapeutics at a glance

- **Ticker**: DCOY

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $8.3 million

### Related companies

- [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) NASDAQ: DMAC
- [City Therapeutics](https://aibio.space/companies/city-therapeutics/) NASDAQ: CTY
- [Janux Therapeutics](https://aibio.space/companies/janux-therapeutics/) NASDAQ: JANX
- [Regen Biopharma](https://aibio.space/companies/regen-biopharma/) OTC: RGBP
- [Generate Biomedicines](https://aibio.space/companies/generate-biomedicines/) NASDAQ: GENB
- [CG Oncology](https://aibio.space/companies/cg-oncology/) NASDAQ: CGON
- [Alto Neuroscience](https://aibio.space/companies/alto-neuroscience/) NYSE: ANRO
- [ALX Oncology Holdings](https://aibio.space/companies/alx-oncology/) NASDAQ: ALXO

### Also on NASDAQ

- [Compugen](https://aibio.space/companies/compugen/) CGEN
- [Artelo Biosciences](https://aibio.space/companies/artelo-biosciences/) ARTL
- [NRX Pharmaceuticals](https://aibio.space/companies/nrx-pharmaceuticals/) NRXP
- [Editas Medicine](https://aibio.space/companies/editas-medicine/) EDIT
- [NeuroPace](https://aibio.space/companies/neuropace/) NPCE
- [Rapport Therapeutics](https://aibio.space/companies/rapport-therapeutics/) RAPP

## Decoy Therapeutics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$368,170](https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/) | [$770,027](https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/) |
| Net income (loss) | [-$12.5 million](https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/) | [-$5.6 million](https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/) |
| Cash from operations | [-$4.8 million](https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/) | [-$4.5 million](https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/) |
| Cash and equivalents | [$10.7 million](https://www.sec.gov/Archives/edgar/data/1615219/000119312526346852/) | [$2.4 million](https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $8.3 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Decoy Therapeutics

Did Decoy Therapeutics do a reverse stock split?

Our latest story on this, dated Apr 25, 2025: "Salarius Pharmaceuticals (now Decoy Therapeutics) gets Nasdaq delisting notice, plans appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/salarius-pharmaceuticals-now-decoy-therapeutics-gets-nasdaq-delisting/).

Was Decoy Therapeutics delisted?

Our latest story on this, dated Jan 2, 2026: "Salarius Pharmaceuticals (now Decoy Therapeutics) gets Nasdaq delisting notice, will appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/salarius-pharmaceuticals-now-decoy-therapeutics-gets-nasdaq-delisting-2/).

Has Decoy Therapeutics raised money recently?

Our latest story on this, dated Oct 6, 2025: "Salarius (now Decoy Therapeutics) says share sales lift equity above Nasdaq minimum". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/salarius-now-decoy-therapeutics-says-share-sales-lift-equity-above/).

Is Decoy Therapeutics involved in a merger or acquisition?

Our latest story on this, dated Jun 11, 2025: "Salarius (now Decoy Therapeutics) cuts its valuation to $2.31 million in merger deal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/salarius-now-decoy-therapeutics-cuts-valuation-2-31-million-merger/).

What is the ticker symbol of Decoy Therapeutics?

Decoy Therapeutics Inc. trades under the ticker DCOY on NASDAQ.

Where is Decoy Therapeutics listed?

Decoy Therapeutics Inc. is listed on NASDAQ.

What is the SEC CIK of Decoy Therapeutics?

The SEC Central Index Key (CIK) for Decoy Therapeutics Inc. is 1615219. Its filings are on SEC EDGAR.

How many shares does Decoy Therapeutics have outstanding?

655,185 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12.

Which country or territory is Decoy Therapeutics listed under?

Our directory records Decoy Therapeutics Inc. under United States.

What does Decoy Therapeutics do?

Our directory classifies Decoy Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Decoy Therapeutics?

The ISIN recorded for Decoy Therapeutics Inc. is US79400X6022.

Does aibio.space cover Decoy Therapeutics?

aibio.space lists Decoy Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Decoy Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

Is Decoy Therapeutics profitable?

Decoy Therapeutics Inc. reported a net loss of $12.5 million for the fiscal year ended Dec 31, 2025, and used $4.8 million of cash in operations, per its annual report to the SEC.

How much does Decoy Therapeutics spend on research and development?

$368,170 in the fiscal year ended Dec 31, 2025, per its annual report.

## Investor discussion: Decoy Therapeutics

Members talk about Decoy Therapeutics (DCOY). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Decoy Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-06-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000119312526286737/dcoy-ex99_1.htm)
2. 2026-04-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000119312526139145/dcoy-ex99_1.htm)
3. 2026-03-05 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000119312526092748/dcoy-ex99_1.htm)
4. 2026-02-25 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000119312526068813/dcoy-20260224.htm)
5. 2026-01-09 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1615219/000119312526008944/d70714ddef14a.htm)
6. 2026-01-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521926000005/flks-20251231.htm)
7. 2025-12-29 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1615219/000119312525335395/d70714dpre14a.htm)
8. 2025-11-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000166/flks-20251117.htm)
9. 2025-11-13 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.02,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000162/flks-20251111.htm)
10. 2025-11-12 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1615219/000162828025051365/slrxdecoyfinal424b4.htm)
11. 2025-10-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000145/flks-20251010.htm)
12. 2025-10-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000142/flks-20251006.htm)
13. 2025-09-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000125/flks-20250904.htm)
14. 2025-08-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000119/flks-20250827.htm)
15. 2025-08-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000162828025041043/exhibit991-8xk.htm)
16. 2025-08-15 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000101/flks-20250815.htm)
17. 2025-08-15 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000105/slrx-formsx3atmprosupp2025.htm)
18. 2025-07-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000076/flks-20250728.htm)
19. 2025-07-21 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000072/flks-20250718.htm)
20. 2025-07-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000069/flks-20250710.htm)
21. 2025-07-08 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000066/flks-20250708.htm)
22. 2025-06-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000064/flks-20250611.htm)
23. 2025-06-11 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000062/flks-20250610.htm)
24. 2025-05-27 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000057/slrx-2025proxystatement052.htm)
25. 2025-05-15 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000051/slrx-2025proxystatementupd.htm)
26. 2025-04-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000045/flks-20250423.htm)
27. 2025-03-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000040/flks-20250326.htm)
28. 2025-01-13 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000004/a991fs2022and2023.htm)
29. 2024-12-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1615219/000161521924000092/flks-20241212.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:DCOY on TradingView](https://www.tradingview.com/symbols/NASDAQ-DCOY/).

## SEC filings and registration

- **SEC name**: Decoy Therapeutics Inc.

- **CIK**: 1615219

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: DCOY (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 2450 HOLCOMBE BLVD, HOUSTON, TX, 77021

- **Phone**: 346-772-0346

- **Shares outstanding**: 655,185 as of 2026-08-12 (10-Q filed 2026-08-12)

- **Former names**: Salarius Pharmaceuticals, Inc.; Flex Pharma, Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [S-1](https://www.sec.gov/Archives/edgar/data/1615219/000119312526417053/dcoy-20261007.htm) filed 2026-10-07
- [8-K](https://www.sec.gov/Archives/edgar/data/1615219/000161521926000019/dcoy-20260922.htm) filed 2026-09-23
- [8-K](https://www.sec.gov/Archives/edgar/data/1615219/000161521926000016/dcoy-20260914.htm) filed 2026-09-15
- [10-Q](https://www.sec.gov/Archives/edgar/data/1615219/000119312526346852/dcoy-20260630.htm) filed 2026-08-12
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1615219/000119312526332762/dcoy_-_special_meeting_d.htm) filed 2026-08-04
- [8-K](https://www.sec.gov/Archives/edgar/data/1615219/000119312526304949/dcoy-20260714.htm) filed 2026-07-15
- [S-1](https://www.sec.gov/Archives/edgar/data/1615219/000119312526300954/dcoy-20260710.htm) filed 2026-07-10
- [8-K](https://www.sec.gov/Archives/edgar/data/1615219/000119312526286737/dcoy-20260626.htm) filed 2026-06-29

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001615219), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Decoy Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DCOY, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Decoy Therapeutics Inc.

- **Ticker**: DCOY

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US79400X6022

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-DCOY/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/decoy-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Decoy Therapeutics (DCOY) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/decoy-therapeutics/